Earlier this month, we covered Definium Therapeutics’ second Phase 3 readout, this time pertaining to its first LSD (DT120) for generalised anxiety disorder (GAD) study. (See Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD.) As the dust settles on the first topline data from that program, we take a closer look through discussion with company management as…
